Natural Killer Cells: Angels and Devils for Immunotherapy

International Journal of Molecular Sciences Review Natural Killer Cells: Angels and Devils for Immunotherapy Beatriz Martín-Antonio 1,2,*ID , Guillermo Suñe 1,2, Lorena Perez-Amill 1, Maria Castella 1,2 and Alvaro Urbano-Ispizua 1,2 1Department of Hematology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; [email protected] (G.S.); [email protected] (L.P.-A.); [email protected] (M.C.); [email protected] (A.U.-I.) 2Josep Carreras Leukaemia Research Institute, 08036 Barcelona, Spain *Correspondence: [email protected]; Tel.: +34-93-227-5400 (ext. 4528) Received: 1 August 2017; Accepted: 19 August 2017; Published: 29 August 2017 Abstract: In recent years, the relevance of the immune system to fight cancer has led to the development of immunotherapy, including the adoptive cell transfer of immune cells, such as natural killer (NK) cells and chimeric antigen receptors (CAR)-modified T cells. The discovery of donor NK cells’ anti-tumor activity in acute myeloid leukemia patients receiving allogeneic stem cell transplantation (allo-SCT) was the trigger to conduct many clinical trials infusing NK cells. Surprisingly, many of these studies did not obtain optimal results, suggesting that many different NK cell parameters combined with the best clinical protocol need to be optimized. Various parameters including the high array of activating receptors that NK cells have, the source of NK cells selected to treat patients, different cytotoxic mechanisms that NK cells activate depending on the target cell and tumor cell survival mechanisms need to be considered before choosing the best immunotherapeutic strategy using NK cells. In this review, we will discuss these parameters to help improve current strategies using NK cells in cancer therapy. Moreover, the chimeric antigen receptor (CAR) modification, which has revolutionized the concept of immunotherapy, will be discussed in the context of NK cells. Lastly, the dark side of NK cells and their involvement in inflammation will also be discussed. Keywords: natural killer (NK); immunotherapy; tumor cell survival mechanisms; inflammation 1. Natural Killer (NK) Cell Modulation Activity Natural killer (NK) cells are cells of the innate immune system with high anti-tumor, antiviral and antimicrobial activity. In healthy individuals, 90% of NK cells in peripheral blood (PB) are mature and cytotoxic, and characterized by the expression of CD16 bright and CD56 dim . The remaining 10% of NK cells represent the immature subset of NK cells that are cytokine producers, and express CD16 dim or CD16 − , CD56 bright and CD25 + [ 1 ]. The activity of NK cells is modulated by an array of inhibitory and activating receptors, which are fundamental in controlling NK cell activity. Whereas inhibitory Killer-cell immunoglobulin-like (KIR) receptors inhibit NK cell cytotoxicity by interacting with the Human Leukocyte Antigen (HLA)-I in human cells, activating receptors activate NK cells by interacting with their ligands in target cells induced upon tumor transformation, viral infection and cell stress. In physiological conditions, inhibitory KIR-HLA-I interaction holds NK cell cytotoxicity against normal cells in the body. However, when a KIR-HLA-I mismatch or HLA-I down-regulation occurs after viral infection or in some tumor cells, inhibitory KIRs cannot interact with their ligands activating NK cell cytotoxic function [ 2 ]. This finding observed by Ruggeri et al. in 2002 in acute myeloblastic leukemia (AML) patients after allogeneic stem cell transplantation (allo-SCT), allowed using the Int. J. Mol. Sci. 2017,18, 1868; doi:10.3390/ijms18091868 www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2017,18, 1868 2 of 20 inhibitory KIR (donor)-HLA-I (patient) mismatch as a prognostic factor in AML patients receiving an allo-SCT [ 3 ]. This “missing self” recognition leads to allo-reactivity after allo-SCT, and consequently, NK cells lyse leukemia blasts, recipient dendritic cells (DCs) and recipient T cells, which translates into a reduction of relapse, prevention of Graft vs. Host Disease (GVHD), and prevention of graft rejection, respectively. The “missing self” recognition led to the proposal of the “missing ligand model” as a powerful algorithm to predict a potent anti-leukemia effect and, consequently, a favorable outcome after allo-SCT [ 3 , 4 ]. However, in non-myeloid malignancies, such as acute lymphoblastic leukemia (ALL), the GVHD reduction and prevention of graft rejection was not always accompanied by an increase of the graft vs. leukemia effect observed in AML [ 5 ]. These conflicting results led to applying the “missing ligand model” mostly in AML [ 6 ], and in non-myeloid malignancies to use this model just for NK-mediated killing of DCs and T cells to predict a reduced GVHD and reduced graft rejection, respectively. The graft vs. leukemia effect occurring mostly in AML could be mediated by HLA down-regulation, which does not occur in other malignancies such as ALL. To support this, clinical studies in ALL confirmed that low HLA-I expression levels in blasts conferred a beneficial effect mediated by allo-reactive NK cells [7]. However, NK cells have a high variety of activating receptors, which also modulate their cytotoxic activity. These receptors will play a fundamental role in the recognition of other types of tumor cells which do not down-regulate HLA-I. Some of these receptors are expressed only at given stages of differentiation or by specific NK cell subsets [ 8 ]. Surprisingly, this high number of activating receptors in NK cells is responsible for the existence of 6000–30,000 different phenotypic NK populations in each healthy individual, which provide flexibility to respond to pathogens and tumor cells [ 9 ]. Activating receptors include different families such as the: (i) activating KIRs which interact with TYRO protein tyrosine kinase binding protein (DAP-12); (ii) C-type lectin-like receptors, including the activating CD94/NKG2C and NKG2D. NKP80, included in this family, exerts an autonomous control of NK cells against excessive inflammatory response causing self-NK cells mediated cytolysis [ 10 – 12 ]; (iii) natural cytotoxicity receptors (NCR) which include NKP30, NKP44 and NKP46 and interact with ligands overexpressed on tumor cells and viral infected cells; and (iv) signaling lymphocyte activating molecule (SLAM) family of receptors which include SLAMF1, 2B4, NTB-A, CD48, CD84, Ly9, and CRACC. They transmit activating signals to mediate NK cytotoxicity. Moreover, NK cells express CD16, which is the Fc receptor that binds Ig-G mediating antibody dependent cellular cytotoxicity (ADCC). 2. NK Cell Classic Cytotoxicity Mechanisms Upon recognition, NK cells eliminate target cells rapidly (within 30–60 min) by different mechanisms. The two classic NK cell cytotoxic mechanisms include the death receptor pathway and the granule dependent pathway. The death receptor pathway is activated by the tumor necrosis factor (TNF)-related apoptosis inducing ligand family (TRAIL) and by Fas-Ligand (FASL) (CD95L) which are expressed on NK cells [ 13 ], and interact with their ligands in target cells. Interaction of FASL with FAS and TRAIL with TRAIL receptors allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase-8, and caspase-10 [ 14 ]. Activation of caspase-8 results either in direct activation of the other caspases or in the proteolysis of Bid, with release of cytochrome C and subsequent caspase activation. Even if it were believed that these receptors only activate apoptosis, new studies have revealed that other types of non-apoptotic inflammatory types of cell death can be activated [ 15 , 16 ]. The granule dependent pathway is initiated after NK cells adhere to the target cell, with subsequent delivery of cytotoxic granules containing perforin and proteases called Granzymes toward the bound target cell [ 17 ]. In humans, there are five different types of Granzymes (A, B, H, K and M) and each one will activate different cell death pathways, either apoptotic or non-apoptotic. Granzymes A and B are the most studied ones. Whereas Granzyme B activates apoptosis through activation of caspases or release of cytochrome C from the mitochondria, apparently, Granzyme A activates non-apoptotic cell death [ 18 ]; however, there are conflicting results regarding the cytotoxic role of Granzyme A [ 19 ]. The other Granzymes have been Int. J. Mol. Sci. 2017,18, 1868 3 of 20 less studied, although it has been shown that Granzyme K is released by CD56bright cells mediating non-apoptotic tumor cell death [ 20 ]. Granzyme M shows anti-tumor properties after adoptive NK cell transfer [ 21 ]. Granzyme H helps Granzyme B kill adenovirus-infected cells [ 22 ]; and Granulysin, which is another NK cytotoxic molecule released in the cytotoxic granules, activates Endoplasmatic Reticulum stress leading to cell death [ 23 ]. All these different cytotoxicity mechanisms that NK cells show, enable them to eliminate different types of tumor cells with their intrinsic characteristics. 3. Immunotherapy Strategies Using NK Cells As previously mentioned, the anti-tumor NK cell activity described after allo-SCT added to the finding that unlike donor T cells, NK cells do not induce GVHD, led to the development of many clinical trials infusing NK cells in patients receiving an SCT. We have reviewed published studies infusing NK cells as an immunotherapy option. Results are not optimal; they are summarized in Table 1. In most of these studies, NK cells were activated in vitro and/or in vivo with Interleukin (IL)2, and administered after immunosuppressive treatment based on fludarabine and cyclophosphamide. Patient disease, disease status, number of NK cells infused and number of NK cell infusions differed from one study to another. All published studies agree that NK cell infusion is a safe and well-tolerated procedure and does not associate to GVHD. Whereas, for myeloid malignancies, most studies used NK cells from haploidentical donors considering the KIR-HLA-I mismatch, in non-myeloid malignancies, NK cells were either autologous or allogeneic and expanded in vitro. In myeloid malignancies, haploidentical NK cells with KIR-HLA-I mismatch have been used either as a consolidation therapy [ 24 , 25 ] or in high risk and refractory patients [ 26 , 27 ]. As a consolidation therapy, in both children with AML and elderly AML patients, NK cells showed a clear benefit. After a median follow up of four years, pediatric patients remain in remission, and elderly patients with high risk AML showed prolonged disease free survival (DFS) after NK cell infusion [ 24 , 25 , 28 ]. These studies concluded that NK cells could be a promising consolidation therapy strategy in patients who are not candidates for receiving an allo-SCT. Another novel consolidation therapy strategy in AML consisted on the infusion of NK cells derived from hematopoietic progenitor cells (HPC) obtained from a cord blood (CB) unit. This technique allowed obtaining enough number of NK cells which were well tolerated. Unlike other procedures, this study did not administrate IL2 into patients, and responses were detected, suggesting that this technique allows obtaining effective NK cells which might be used off-the-shelf when required [29]. In refractory patients, results are not good. However, it was noticed that infusion of haploidentical NK cells combined with IL2 diphtheria toxin fusion protein (IL2DT) to deplete host T-reg cells led to higher NK cell expansion, improved complete remission rate and disease-free survival with no increased toxicity in AML patients [ 26 ]. Lee et al. also showed durable responses associated with CD56+ cells delivered in myeloid malignancies [ 27 ]. Another study in AML and MDS found resolution of dysplastic features in 50% of myelodisplastic sindrome (MDS) patients, and 16% of complete remission (CR) in AML; however, they could not find NK cells in peripheral blood (PB) [ 30 ]. In pediatric refractory AML patients who received or did not receive an allo-SCT previously, responses higher than 50% were detected after NK infusion, and combined with allo-SCT afterwards, 27% and 36% of DFS were achieved, respectively, at six years [ 31 ]. Another approach tested in high risk AML patients, consisted in the infusion of haploidentical NK cells previously primed with tumor cell lysates. IL2 was not administrated to patients, and still NK cells seemed to exert anti-leukemia effect in 57% of the patients. However, at 2 years 85.7% patients died [ 32 ]. Studies in myeloid malignancies indicated that better responses were achieved when infusing NK cells in patients in remission suggesting that NK cells cannot overcome large tumor burdens. Therefore, more recent approaches aim at expanding NK cells in vitro to obtain a high number of NK for large tumor mass. Int. J. Mol. Sci. 2017,18, 1868 4 of 20 Table 1. Clinical studies performed with NK (natural killer) cells as immunotherapy treatment. nPatients Disease NK Source Treatment before NK Infusion NK Activation Detection of NK in PB Median Number of Infused NK (×106/Kg) Graft vs. Host Disease Outcome. Clinical Trial Number (Reference) 10. AML in CR (pediatric) Haplo Flu/Cy IL2 post-infusion Yes 29 No All in remission at 964 days [24] 13. AML: 38.4% in AD, 15.3% MR, 46% CR Haplo Flu/Cy IL2 post-infusion Yes 2.74 No AD: 20% achieved transient CR MR: 100% achieved CR CR: 50% DFS after 34, 32, 18 months. NCT00799799 [25] 16. AML in CR Haplo Flu/Cy IL2 post-infusion Yes From 1.29 to 5.53 No At 22.5 months: 56% DFS, 44% relapse. Higher NK cell number associated to higher DFS. NCT00799799 [28] 10. AML in CR Allo NK derived from CD34+ HSPC from CB Flu/Cy IL15 and IL2 Yes (in 21%) From 3 to 30 No 20% became MRD negative for 6 months [29] 57. Refractory AML (15 received IL2DT) Haplo Flu/Cy IL2 post-infusion Yes: in 10% of patients, and in 27% of patients receiving IL2DT) 26 No CR: 53% (IL2DT) vs. 21% (no IL2DT) DFS: 33% (IL2DT) vs. 5% (no IL2DT) NCT00274846, NCT01106950 [26] 21. AML, MDS, CML Haplo Flu, Bu IL2 pre and post-infusion NA From 0.22 to 8.32 No associated to NK Survival associated with CD56+ cells delivered; 24% durable CR (no association to KIR-HLA mismatch). NCT00402558. NCT01390402 [27] Refractory 6: AML, 2: MDS Haplo Flu/Cy IL2 post-infusion No 10.6 No 16% CR; 83% Disease progression. NCT00871689 [30] 29. Pediatric refractory AML Cohort 1: no prior allo-SCT (14) Cohort 2: relapsed after allo-SCT (15) Haplo Clo/Eto/Cy IL2 post-infusion Yes From 3.5 to 103 No Cohort 1: 71% response; 86% underwent allo-SCT; 36% DFS at 6 years. Cohort 2: 66.6% response and underwent allo-SCT; 27% DFS at 6 years. NCT00697671 and NCT00187096 [31] 7. High risk AML Haplo Flu/TBI Tumor-primed NK cells with tumor lysate Yes 3 doses: 1, 5, 10 No At 6 months: 42.8% in CR remained in remission, 14% in PR achieved CR, 28% relapse, 14% died. At 1 year: 14% remained in CR. At 2 years: 85.7% died. Median OS: 400 days [32] 10. Relapsed MM Haplo Flu/Mel/Dx IL2 pre and post infusion Yes (until day 14) 1.7 No 50% CR or near CR, 20% PR, 10% SD and 20% PD [33] 17. Lymphoma (2), advanced solid tumors (15) Allo Non immunosuppressive regimen IL2 (MG4101 method) Yes From 1 to 30 (1 and 3 doses) No Lymphoma: 50% SD, 50% PD Solid tumors: 47% SD, 53% PD. PFS in SD: 4 months. NCT01212341 [34] 5. Relapsed MM Auto Len, Bort IL2, K562-mb15-41BBL cells Yes (7.5)x2 No 80% disease stabilization; 40–50% reduction in BM. NCT02481934 [35] Int. J. Mol. Sci. 2017,18, 1868 5 of 20 Table 1. Cont. nPatients Disease NK Source Treatment before NK Infusion NK Activation Detection of NK in PB Median Number of Infused NK (×106/Kg) Graft vs. Host Disease Outcome. Clinical Trial Number (Reference) 8. Relapsed MM Auto/Haplo Bort/Cy/Dx/Flu K562-mb15-41BBL cells IL2 post-infusion Yes (in 62%) 100 No 28% partial response [36] 12. Relapsed MM CB Len/Mel K562-mb21-41BBL cells Yes (in 50%) 4 doses: 5 , 10, 50 and 100 No 83% VGPR, 66% NCR; 33% relapse (at 21 months); 16% dead (at 21 months) [37] 6. Pediatric refractory solid tumors Haplo Flu/Bu/Thio/Mp IL15 Yes From 3 to 27 No 66% clinical response: 16% VGPR, 33% PR, 16% SD. At 310 days all patients died. NCT01337544 [38] 14. Ovarian 6. Breast Haplo Flu/Cy/TBI (in 7 pt) IL2 pre and post-infusion In 1 patient (no detection associated to T-reg presence) 21.6 No Toxicity associated to TLS. NCT01105650 [39] 61.Hepatocellular carcinomoa Cryosurgery (26) Cryosurgery+NK (35) Allo Cryosurgery K562-based system NA NA No Increased PFS: 9.1 vs. 7.6 months Increased Response rate: 60% vs. 46.1% Increased disease control rate: 85.7% vs. 69.2% [ 40 ] 7. Metastatic melanoma 1. Renal cell carcinoma Auto Flu/Cy IL2 Yes 4.7 No 0% response. NCT00328861 [41] 5. CRC (1), .HC (1), RCC (2), CLL (1) Allo Ta/Mp (in 2 patients) IL2 pre and post Yes From 1 to 50 No 20% PR [42] Haplo: haploidentical; Allo: allogeneic; Allo-SCT: allogeneic stem cell transplantation; Flu: Fludarabine; Bu: Busulfan, ATG: Anti-Thymocyte Globulin; Ta: Tacrolimus, Mx: Methotrexate; Cy: Cyclophosphamide; Cs: Cyclosporine; Len: Lenalidomide; Bort: Bortezomib; Dex: Dexamethasone; Mel: Melphalan; Clo: Clofarabine, Eto: Etoposide; Thio: thiotepa; Mp: methylprednisolone; TBI: total body irradiation; TLS: tumor lysis syndrome; BM: bone marrow; AML: acute myeloid leukemia; MDS: myelodisplastic sindrome; CML: chronic Myeloid Leukemia; CLL: Chronic Lymphocytic Leukemia; NHL: Non-Hodgkin Lymphoma; MM: multiple myeloma; HC: Hepatocellular carcinoma; CRC: colorectal carcinoma; RCC: Renal cell carcinoma; CB: cord blood; HSPC: hematopoietic stem progenitor cells; VGPR: very good partial response; NCR: near complete response; PR: partial response; CR: complete remission; AD: active disease; MR: molecular relapse; SD: stable disease; PB: peripheral blood; PD: progressive disease; PFS: progression free survival; DFS: disease free survival; OS: overall survival; NA: information not provided in the study; IL2DT: IL2 diphtheria toxin fusion protein; NA: information not specified. Int. J. Mol. Sci. 2017,18, 1868 6 of 20 In non-myeloid malignancies, both haploidentical NK cells and NK cells expanded in vitro from other sources have been used. Infusion of haploidentical NK cells in multiple myeloma (MM) relapsed patients, before an autologous-SCT (auto-SCT), obtained 50% of complete or near complete responses [ 33 ]. Yang et al. expanded allogeneic NK cells in vitro allowing infusion of repetitive administrations of NK cells in advanced lymphoma and advanced solid tumors. They found that activated and expanded NK cells are also safe obtaining 47.1% of stable disease. Interestingly, they observed that T-reg cells and myeloid-derived suppressor cells were reduced after NK administration [ 34 ]. In relapsed MM, different protocols infusing in vitro expanded NK cells with K562 artificial Antigen Presenting Cells (aAPCs) have been tested. For instance, Leivas et al. combining autologous expanded NK cells with anti-MM drugs (Lenalidomide/Bortezomib) showed 80% of disease stabilization and that the combination of NK cells with Lenalidomide was the best one. They did not administrate IL2 into the patients [ 35 ]. Szmania et al. infused either autologous or haploidentical expanded NK cells combined with Bortezomib-Dexamethasone based anti-MM treatment, and IL2 in vivo administration, obtaining much lower responses (28% PR) [ 36 ]. Shah et al. [ 37 ] infused expanded NK cells derived from a CB unit (CB-NK) and combined them with Lenalidomide before auto-SCT. Eighty-three percent of patients showed very good partial responses; at 21 months, 33% of patients relapsed. These three studies showed that NK cell in vitro expansion using aAPC K562-based system is an efficient technique to obtain a high number of activated NK cells, which are safe for patients. The NK cells in vitro expansion technique with aAPC K562-based system can be visualized in Figure 1. Int. J. Mol. Sci. 2017, 18, 1868 6 of 20 In non-myeloid malignancies, both haploidentical NK cells and NK cells expanded in vitro from other sources have been used. Infusion of haploidentical NK cells in multiple myeloma (MM) relapsed patients, before an autologous-SCT (auto-SCT), obtained 50% of complete or near complete responses [33]. Yang et al. expanded allogeneic NK cells in vitro allowing infusion of repetitive administrations of NK cells in advanced lymphoma and advanced solid tumors. They found that activated and expanded NK cells are also safe obtaining 47.1% of stable disease. Interestingly, they observed that T-reg cells and myeloid-derived suppressor cells were reduced after NK administration [34]. In relapsed MM, different protocols infusing in vitro expanded NK cells with K562 artificial Antigen Presenting Cells (aAPCs) have been tested. For instance, Leivas et al. combining autologous expanded NK cells with anti-MM drugs (Lenalidomide/Bortezomib) showed 80% of disease stabilization and that the combination of NK cells with Lenalidomide was the best one. They did not administrate IL2 into the patients [35]. Szmania et al. infused either autologous or haploidentical expanded NK cells combined with Bortezomib-Dexamethasone based anti-MM treatment, and IL2 in vivo administration, obtaining much lower responses (28% PR) [36]. Shah et al. [37] infused expanded NK cells derived from a CB unit (CB-NK) and combined them with Lenalidomide before auto-SCT. Eighty-three percent of patients showed very good partial responses; at 21 months, 33% of patients relapsed. These three studies showed that NK cell in vitro expansion using aAPC K562-based system is an efficient technique to obtain a high number of activated NK cells, which are safe for patients. The NK cells in vitro expansion technique with aAPC K562-based system can be visualized in Figure 1. Figure 1. Clinical expansion of Natural Killer (NK) cells from apheresis products or cord blood (CB) units. Activated NK cells can be generated starting either from mononuclear cells (MNC) or with magnetically selected NK cells. First, either CB or apheresis products are ficolled to get the MNC, and then they are either added directly to a bio-reactor or subjected to magnetic CD56+ selection. These CD56+ cells will be added to the bio-reactor. Then, they are expanded in vitro for seven days with artificial antigen presenting cells (aAPCs). IL2 is added exogenously every other day. aAPCs are K562-based aAPCs expressing 41BB ligand, CD64, CD86 and either membrane bound IL21 or IL15. They are co-cultured in a 2:1 aAPC:MNC or NK cells ratio. On Day 7, fresh aAPCs are added again in the same ratio and co-cultured in the same conditions for an additional seven days. On Day 7 and Day 14, cells are CD3-depleted, only in case the expansion was started with MNC. Expansion can be continued for a total of 4 weeks repeating the same procedure. PB: peripheral blood. In the context of non-hematological malignancies, haploidentical NK cells have been used with no optimal results. In pediatric patients with refractory solid tumors, haploidentical NK cells were infused after haplo-SCT. No toxic effects were observed, and 66% of the patients showed a clinical Figure 1. Clinical expansion of Natural Killer (NK) cells from apheresis products or cord blood (CB) units. Activated NK cells can be generated starting either from mononuclear cells (MNC) or with magnetically selected NK cells. First, either CB or apheresis products are ficolled to get the MNC, and then they are either added directly to a bio-reactor or subjected to magnetic CD56+ selection. These CD56+ cells will be added to the bio-reactor. Then, they are expanded in vitro for seven days with artificial antigen presenting cells (aAPCs). IL2 is added exogenously every other day. aAPCs are K562-based aAPCs expressing 41BB ligand, CD64, CD86 and either membrane bound IL21 or IL15. They are co-cultured in a 2:1 aAPC:MNC or NK cells ratio. On Day 7, fresh aAPCs are added again in the same ratio and co-cultured in the same conditions for an additional seven days. On Day 7 and Day 14, cells are CD3-depleted, only in case the expansion was started with MNC. Expansion can be continued for a total of 4 weeks repeating the same procedure. PB: peripheral blood. Int. J. Mol. Sci. 2017,18, 1868 7 of 20 In the context of non-hematological malignancies, haploidentical NK cells have been used with no optimal results. In pediatric patients with refractory solid tumors, haploidentical NK cells were infused after haplo-SCT. No toxic effects were observed, and 66% of the patients showed a clinical response. However, all patients had died after 310 days [ 38 ]. In adults with recurrent ovarian and breast cancer, the beneficial effect of NK cells could not be differentiated from the chemotherapy regimen [ 39 ]. Another approach in hepatocellular carcinoma combined allogeneic in vitro expanded NK cells showing KIR-HLA-I mismatch with cryosurgery. Beneficial effects were detected in terms of enhanced immune function, increased progression free survival (PFS) and improved of patients’ quality of life [ 40 ]. In metastatic melanoma and renal cell carcinoma, autologous NK cells did not show any anti-tumor activity. Although NK cells persisted in PB they had lost NKG2D expression and needed to be re-activated with IL2 [ 41 ]. In 2008, Alici et al. also developed a technique to expand NK cells without the need of feeder cells. They managed to obtain a high number of activated NK cells starting from Peripheral Blood Mononuclear Cells (PBMC), by adding anti-CD3 antibody for the first five days and IL2 [ 43 ]. Afterwards, they compared different expansion systems by using flasks, cell culture bags and bioreactors and showed that bioreactors without the need of feeder cells obtained the best results [ 44 ]. Afterwards, they used this technique in a clinical trial with five refractory cancer patients who received donor-derived expanded NK cells after allo-SCT. In one patient (20%) with hepatocellular carcinoma partial responses were observed with markedly decreased serum alpha-fetoprotein levels [ 42 ]. Of interest, other type of feeder cells (Epstein-Barr virus immortalized lymphoblastoid B-cell lines: EBV-LCL) have also been tested to expand NK cells, also obtaining a high number of activated NK cells with efficient anti-tumor activity in mouse melanoma models [ 45 ]. More information about clinical studies infusing activated NK cells into patients has been addressed in other reviews [46]. All these studies demonstrated that: (1) there is a lack of expansion and persistence of NK cells in PB at long term, which is due to allo-reactive T cells eliminating NK cells [ 47 , 48 ]; (2) the negative immunosuppressive effect of T-reg cells might be improved with the use of IL2DT [ 26 ]; (3) NK cells might be a better choice for consolidation therapy rather than for refractory patients; (4) in non-myeloid refractory malignancies, NK cells do not achieve durable responses and the KIR-HLA-I ligand mismatch might not be always efficient. Moreover, after NK in vitro expansion, the KIR-HLA-I mismatch effect in some occasions can be bypassed, and the expression of NK receptors become homogenous because of the expansion. Therefore, in non-myeloid malignancies, activating receptors could be more relevant [ 49 , 50 ]; (5) different expansion techniques such as the aAPC K562-based system, NK cells derived from HPC and NK-92 cell line have been developed to overcome the limitation in obtaining large number of NK cells for the treatment of large tumor masses. These techniques allow obtaining a high number of NK cells ready to infuse off-the-shelf [29]. 4. Chimeric Antigen Receptors (CAR) Modified NK Cells Whereas CAR-T cell therapy has appeared in the last years as a revolutionary immunotherapy option for the treatment of hematological malignancies, CAR-modified NK cells is a field still under development. A CAR is a chimeric molecule composed of three regions: (1) an extracellular domain derived from the single chain variable fragment (scFV) of a monoclonal antibody (mAb), which redirects the specificity of T cells towards a specific target expressed in tumor cells without the need of antigen presentation; (2) a transmembrane domain; and (3) an intracellular domain derived from the ζ chain of the T cell receptor (TCR)/CD3 complex which activates the lytic pathway of T cells. Moreover, co-stimulatory signaling endodomains (CD28, 4-1BB or OX40) activate T cell proliferation after encounter of the target cell. The number of co-stimulatory domains can differ between the different CAR [ 51 ]. First clinical studies infusing CAR-T cells showed the efficacy of these cells in refractory patients [ 52 ]; consequently, an increasing number of clinical studies infusing CAR-T cells are currently being executed. Int. J. Mol. Sci. 2017,18, 1868 8 of 20 The intrinsic anti-tumor activity of NK cells added to the high number of activating receptors that initiate their cytotoxic activity would lead us to hypothesize that NK cells do not need a CAR. However, the negative clinical results infusing NK cells, especially in refractory patients, indicate that other options are needed. The addition of a CAR into NK cells might add an additional mechanism of tumor cell recognition, specifically useful in patients with down-regulation of the ligands required for activation of NK receptors. Furthermore, after recognizing the tumor cell, the CAR will induce NK cell proliferation increasing NK cell persistence in patients. However, up to date, only preclinical studies using CAR-NK cells have been published. These include CAR-NK targeting CD19 and CD20 for B cell malignancies [ 53 – 55 ], CD5 for T cell malignancies [ 56 ], and CD138 and CS1 for MM [ 57 , 58 ]. In solid tumors, many preclinical studies have also been published targeting among others Her2, GD2 and EGFR for breast cancer, renal cell carcinoma, ovarian cancer, melanoma, neuroblastoma and glioblastoma [ 59 – 62 ]. Most of these studies have used NK-92 cells. However, other NK cell sources tested include NK cells previously obtained from HPCs [ 63 ], and NK cells from CB and expanded in vitro with aAPC K562-based systems [ 53 ]. More detailed information about current pre-clinical studies on-going with CAR-NK cells can be found in other reviews [64]. Some advances made in these studies indicate that the addition of IL15 into the CAR construct increases NK cell persistence in vivo [ 53 ]. Moreover, the inability of NK cells to traffic to tumor sites has been eliminated by the addition of C-X-X motif chemokine receptor 4 (CXCR4) in the CAR construct [ 65 ]. Clinical studies infusing CAR-NK are very scarce up to date and they are still recruiting patients. These studies target CD19 for B cell malignancies, CD33 for CD33+ AML and CD7 for leukemias and lymphomas. Most of these studies use either NK-92 cells or NK cells expanded in vitro with aAPC K562-based systems. They are summarized in Table 2. Table 2. Clinical studies on-going infusing CAR-NK cells in cancer patients. NCT Number Institution Type of NK/CAR-CoStimulatory Domains Disease Treatment/Doses NCT02892695 PersonGen BioTherapeutics NK-92 Anti-CD19-CD28, 4-1BB Relapsed/refractory ALL, CLL, FL, BCL, DLBCL NK before SCT NCT02944162 PersonGen BioTherapeutics NK-92 Anti-CD33-CD28, CD137 Relapsed/refractory CD33+ AML NK on Days 0, 3 and 5 NCT02742727 PersonGen BioTherapeutics NK92 Anti-CD7CD28, 4-1BB Relapsed/refractory CD7 positive leukemias and lymphomas NK NCT03056339 M.D.Anderson Cancer Center CB-NK expanded with K562-mb21 Anti-CD19, 4-1BB, CD28, iCasp9, IL15 B-cell malignancies: ALL, CLL, NHL Day-5 to -3: Flu, Cy, Mesna Day 0: NK AP1903 in case of CRS or GVHD NCT02839954 PersonGen BioTherapeutics NA Relapsed/refractory Muc1 positive solid tumors NA NCT01974479 National University Health system, Singapore Haploidentical NK expanded with K562-mb15-41BBL Anti-CD19, 4-1BB Refractory ALL NK NCT00995137 St. Jude Children‘s Research Hospital Haploidentical NK expanded with K562-mb15-41BBL Anti-CD19, 4-1BB Refractory ALL NK ALL: acute lympoblastic leukemia; CLL: chronic lymphocytic leukemia; FL: follicular lymphoma; BCL: B cell lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large cell lymphoma; AML: acute myeloid leukemia; NHL: non Hodgkin Lymphoma; Flu: fludarabine; Cy: cyclophosphamide; NA: information not specified 5. CB Derived NK Cells (CB-NK): A Source of Highly Activated NK Cells Which Initiate a Transmissible Cytotoxicity The aAPC K562-based system used to expand NK cells appears as one of the preferred techniques to expand NK cells in all published studies. These cells can have either membrane-bound IL15 or IL21, Int. J. Mol. Sci. 2017,18, 1868 9 of 20 which are required for NK cell differentiation [ 66 ]. Therefore, this system, starting from mononuclear cells, allows obtaining a large number of differentiated NK cells. We have used this technique to expand NK cells from a CB unit. These NK cells are termed CB derived NK cells (CB-NK). At the end of the in vitro expansion, a large number of highly activated NK cells are obtained. Therefore, fully tested and HLA-typed NK cells are available off-the-shelf [ 50 ]. Interestingly, in physiological conditions, the CD56 bright NK cells are the immature population, with longer telomeres than CD56dim NK cells [ 67 ]. However, after in vitro expansion, CB-NK become a CD56bright cell population with a homogenous phenotype in terms of inhibitory KIRs and activating receptors, such as NKG2D and the NCR family of receptors [ 50 ]. Moreover, CB-NK show longer telomeres than freshly obtained NK cells from CB [ 68 ], and are highly activated in terms of both cytokine production and cytotoxicity [43,64]. We have studied the specific cytotoxicity of CB-NK against MM cells, which express HLA-I, and compared it against that of tumor cells with HLA-I down-regulation (K562 cells) [ 69 ]. We observed that CB-NK cytotoxicity differs for each type of tumor cell, in terms of NK cell receptors, cytotoxic molecules and types of cell death activated. Whereas NKG2D and NKP30 activating NK cell receptors do not have any impact in CB-NK cytotoxicity against K562, for MM cells, these receptors as well as NKG2D ligands have a significant role. Moreover, whereas Granzyme B is involved in CB-NK cytotoxicity against K562 cells mediating a Caspase-3 dependent cytotoxicity; in MM cells, Granzyme B does not impact the CB-NK cytotoxicity, which, in addition, is Caspase-3 independent. Moreover, this cytotoxicity against MM cells involves cathepsin release from lysosomes, which mediate a type of cell death termed “lysosomal cell death”. This dependence on cathepsins occurs only in MM cells and not in K562 cells [ 69 ], indicating the variety of cytotoxic mechanisms that NK cells can activate depending on each type of tumor cell. Interestingly, when CB-NK and MM cells become in contact, both NKG2D and NKP30 receptors are transferred to MM cells. This transfer of NK cell receptors co-localizes with lipid structures. When Filipin-III—a lipid raft inhibitor—is added, this NK cell receptor transfer to MM cells decreases, suggesting a role of lipid metabolism in controlling the stability of these receptors in NK cells. NK cell activating receptors are continuously being recycled and degraded by endocytic pathway [ 70 ]. More specifically, the transfer of NKG2D and NKP30 co-localizing with proteins of the endocytic pathway (Rab1, Rab7 and Rab11) was confirmed [ 69 ]. Importantly, the transfer and degradation of these receptors in MM cells, might explain why cancer patients have NK cells that show with down-regulation of activating receptors [71,72]. Moreover, after CB-NK contact, MM cells become stressed and increase cell–cell communication between them. This increased cell–cell contact enables a secondary transfer of NKG2D and NKP30 NK cell receptors from MM cells exposed to CB-NK to neighboring MM cells non-exposed to CB-NK. Interestingly, this secondary transfer between MM cells of CB-NK proteins translates into a transmissible cytotoxicity mediated by MM cells, as initial MM cells exposed to CB-NK are able to transfer lipid-protein vesicles to neighboring MM cells non-exposed to CB-NK, causing cytotoxicity into a proportion of these neighboring MM cells (Figure 2) [69]. Int. J. Mol. Sci. 2017,18, 1868 16 of 20 38. Perez-Martinez, A.; Fernandez, L.; Valentin, J.; Martinez-Romera, I.; Corral, M.D.; Ramirez, M.; Abad, L.; Santamaria, S.; Gonzalez-Vicent, M.; Sirvent, S.; et al. A phase I/II trial of interleukin-15–stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy 2015,17, 1594–1603. [CrossRef] [PubMed] 39. Geller, M.A.; Cooley, S.; Judson, P.L.; Ghebre, R.; Carson, L.F.; Argenta, P.A.; Jonson, A.L.; Panoskaltsis-Mortari, A.; Curtsinger, J.; McKenna, D.; et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011 ,13, 98–107. [CrossRef] [PubMed] 40. Lin, M.; Liang, S.; Wang, X.; Liang, Y.; Zhang, M.; Chen, J.; Niu, L.; Xu, K. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget 2017. [CrossRef] 41. Parkhurst, M.R.; Riley, J.P.; Dudley, M.E.; Rosenberg, S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 2011,17, 6287–6297. [CrossRef] [PubMed] 42. Barkholt, L.; Alici, E.; Conrad, R.; Sutlu, T.; Gilljam, M.; Stellan, B.; Christensson, B.; Guven, H.; Bjorkstrom, N.K.; Soderdahl, G.; et al. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: A phase I clinical study. Immunotherapy 2009 ,1, 753–764. [CrossRef] [PubMed] 43. Alici, E.; Sutlu, T.; Bjorkstrand, B.; Gilljam, M.; Stellan, B.; Nahi, H.; Quezada, H.C.; Gahrton, G.; Ljunggren, H.G.; Dilber, M.S. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008,111, 3155–3162. [CrossRef] [PubMed] 44. Sutlu, T.; Stellan, B.; Gilljam, M.; Quezada, H.C.; Nahi, H.; Gahrton, G.; Alici, E. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010,12, 1044–1055. [CrossRef] [PubMed] 45. Granzin, M.; Stojanovic, A.; Miller, M.; Childs, R.; Huppert, V.; Cerwenka, A. Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma. Oncoimmunology 2016,5, e1219007. [CrossRef] [PubMed] 46. Gao, X.; Mi, Y.; Guo, N.; Xu, H.; Xu, L.; Gou, X.; Jin, W. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy. Front. Immunol. 2017,8, 774. [CrossRef] [PubMed] 47. Bishara, A.; de Santis, D.; Witt, C.C.; Brautbar, C.; Christiansen, F.T.; Or, R.; Nagler, A.; Slavin, S. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004 ,63, 204–211. [CrossRef] [PubMed] 48. Lowe, E.J.; Turner, V.; Handgretinger, R.; Horwitz, E.M.; Benaim, E.; Hale, G.A.; Woodard, P.; Leung, W. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br. J. Haematol. 2003,123, 323–326. [CrossRef] [PubMed] 49. Kim, S.; Poursine-Laurent, J.; Truscott, S.M.; Lybarger, L.; Song, Y.J.; Yang, L.; French, A.R.; Sunwoo, J.B.; Lemieux, S.; Hansen, T.H.; et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005,436, 709–713. [CrossRef] [PubMed] 50. Shah, N.; Martin-Antonio, B.; Yang, H.; Ku, S.; Lee, D.A.; Cooper, L.J.N.; Decker, W.K.; Li, S.; Robinson, S.N.; Sekine, T.; et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS ONE 2013 ,8, e76781. [CrossRef] [PubMed] 51. Dotti, G.; Savoldo, B.; Brenner, M. Fifteen years of gene therapy based on chimeric antigen receptors: “Are we nearly there yet?”. Human Gene Ther. 2009,20, 1229–1239. [CrossRef] [PubMed] 52. Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014,371, 1507–1517. [CrossRef] [PubMed] 53. Liu, E.; Tong, Y.; Dotti, G.; Shaim, H.; Savoldo, B.; Mukherjee, M.; Orange, J.; Wan, X.; Lu, X.; Reynolds, A.; et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent anti-tumor activity. Leukemia 2017. [CrossRef] [PubMed] 54. Shimasaki, N.; Fujisaki, H.; Cho, D.; Masselli, M.; Lockey, T.; Eldridge, P.; Leung, W.; Campana, D. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012,14, 830–840. [CrossRef] [PubMed] Int. J. Mol. Sci. 2017,18, 1868 17 of 20 55. Chu, Y.; Hochberg, J.; Yahr, A.; Ayello, J.; van de Ven, C.; Barth, M.; Czuczman, M.; Cairo, M.S. Targeting CD20 + Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunol. Res. 2015,3, 333–344. [CrossRef] [PubMed] 56. Chen, K.H.; Wada, M.; Pinz, K.G.; Liu, H.; Lin, K.W.; Jares, A.; Firor, A.E.; Shuai, X.; Salman, H.; Golightly, M.; et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia 2017. [CrossRef] [PubMed] 57. Jiang, H.; Zhang, W.; Shang, P.; Zhang, H.; Fu, W.; Ye, F.; Zeng, T.; Huang, H.; Zhang, X.; Sun, W.; et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 2014,8, 297–310. [CrossRef] [PubMed] 58. Chu, J.; Deng, Y.; Benson, D.M.; He, S.; Hughes, T.; Zhang, J.; Peng, Y.; Mao, H.; Yi, L.; Ghoshal, K.; et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 2014,28, 917–927. [CrossRef] [PubMed] 59. Schonfeld, K.; Sahm, C.; Zhang, C.; Naundorf, S.; Brendel, C.; Odendahl, M.; Nowakowska, P.; Bonig, H.; Kohl, U.; Kloess, S.; et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol. Ther. 2015,23, 330–338. [CrossRef] [PubMed] 60. Zhang, C.; Burger, M.C.; Jennewein, L.; Genssler, S.; Schonfeld, K.; Zeiner, P.; Hattingen, E.; Harter, P.N.; Mittelbronn, M.; Tonn, T.; et al. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. J. Natl. Cancer Inst. 2016,108. [CrossRef] [PubMed] 61. Seidel, D.; Shibina, A.; Siebert, N.; Wels, W.S.; Reynolds, C.P.; Huebener, N.; Lode, H.N. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Cancer Immunol. Immunother. 2015,64, 621–634. [CrossRef] [PubMed] 62. Genssler, S.; Burger, M.C.; Zhang, C.; Oelsner, S.; Mildenberger, I.; Wagner, M.; Steinbach, J.P.; Wels, W.S. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncoimmunology 2016,5, e1119354. [CrossRef] [PubMed] 63. Lowe, E.; Truscott, L.C.; de Oliveira, S.N. In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells. Methods Mol. Biol. 2016,1441, 241–251. [PubMed] 64. Rezvani, K.; Rouce, R.; Liu, E.; Shpall, E. Engineering Natural Killer Cells for Cancer Immunotherapy. Mol. Ther. 2017,25, 1769–1781. [CrossRef] [PubMed] 65. Muller, N.; Michen, S.; Tietze, S.; Topfer, K.; Schulte, A.; Lamszus, K.; Schmitz, M.; Schackert, G.; Pastan, I.; Temme, A. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1 α -secreting Glioblastoma. J. Immunother. 2015,38, 197–210. [CrossRef] [PubMed] 66. Sivori, S.; Cantoni, C.; Parolini, S.; Marcenaro, E.; Conte, R.; Moretta, L.; Moretta, A. IL-21 induces both rapid maturation of human CD34 + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 2003,33, 3439–3447. [CrossRef] [PubMed] 67. Romagnani, C.; Juelke, K.; Falco, M.; Morandi, B.; D’Agostino, A.; Costa, R.; Ratto, G.; Forte, G.; Carrega, P.; Lui, G.; et al. CD56 bright CD16 − killer Ig-like receptor − NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J. Immunol. 2007,178, 4947–4955. [CrossRef] [PubMed] 68. Denman, C.J.; Senyukov, V.V.; Somanchi, S.S.; Phatarpekar, P.V.; Kopp, L.M.; Johnson, J.L.; Singh, H.; Hurton, L.; Maiti, S.N.; Huls, M.H.; et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012,7, e30264. [CrossRef] [PubMed] 69. Martin-Antonio, B.; Najjar, A.; Robinson, S.N.; Chew, C.; Li, S.; Yvon, E.; Thomas, M.W.; Mc Niece, I.; Orlowski, R.; Urbano-Ispizua, A.; et al. Transmissible cytotoxicity of Multiple Myeloma cells by NK cells mediated by vesicle trafficking. Cell Death Differ. 2015,22, 96–107. [CrossRef] [PubMed] 70. Masilamani, M.; Peruzzi, G.; Borrego, F.; Coligan, J.E. Endocytosis and intracellular trafficking of human natural killer cell receptors. Traffic 2009,10, 1735–1744. [CrossRef] [PubMed] 71. Huergo-Zapico, L.; Acebes-Huerta, A.; Gonzalez-Rodriguez, A.P.; Contesti, J.; Gonzalez-Garcia, E.; Payer, A.R.; Villa-Alvarez, M.; Fernandez-Guizan, A.; Lopez-Soto, A.; Gonzalez, S. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS ONE 2014,9, e108326. [CrossRef] [PubMed] Int. J. Mol. Sci. 2017,18, 1868 18 of 20 72. Pesce, S.; Tabellini, G.; Cantoni, C.; Patrizi, O.; Coltrini, D.; Rampinelli, F.; Matta, J.; Vivier, E.; Moretta, A.; Parolini, S.; et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 2015,4, e1001224. [CrossRef] [PubMed] 73. Rogers, R.S.; Bhattacharya, J. When cells become organelle donors. Physiology 2013 ,28, 414–422. [CrossRef] [PubMed] 74. Islam, M.N.; Das, S.R.; Emin, M.T.; Wei, M.; Sun, L.; Westphalen, K.; Rowlands, D.J.; Quadri, S.K.; Bhattacharya, S.; Bhattacharya, J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat. Med. 2012,18, 759–765. [CrossRef] [PubMed] 75. Yasuda, K.; Khandare, A.; Burianovskyy, L.; Maruyama, S.; Zhang, F.; Nasjletti, A.; Goligorsky, M.S. Tunneling nanotubes mediate rescue of prematurely senescent endothelial cells by endothelial progenitors: Exchange of lysosomal pool. Aging 2011,3, 597–608. [CrossRef] [PubMed] 76. Xie, J.; Liu, M.; Li, Y.; Nie, Y.; Mi, Q.; Zhao, S. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. Cell. Mol. Immunol. 2014 ,11, 495–502. [CrossRef] [PubMed] 77. Zhang, X.; Rao, A.; Sette, P.; Deibert, C.; Pomerantz, A.; Kim, W.J.; Kohanbash, G.; Chang, Y.; Park, Y.; Engh, J.; et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016,18, 1402–1412. [CrossRef] [PubMed] 78. Song, H.; Kim, J.; Cosman, D.; Choi, I. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell. Immunol. 2006,239, 22–30. [CrossRef] [PubMed] 79. Semeraro, M.; Rusakiewicz, S.; Minard-Colin, V.; Delahaye, N.F.; Enot, D.; Vely, F.; Marabelle, A.; Papoular, B.; Piperoglou, C.; Ponzoni, M.; et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci. Transl. Med. 2015,7. [CrossRef] [PubMed] 80. Weil, S.; Memmer, S.; Lechner, A.; Huppert, V.; Giannattasio, A.; Becker, T.; Muller-Runte, A.; Lampe, K.; Beutner, D.; Quaas, A.; et al. Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma. Front. Immunol. 2017 ,8, 387. [CrossRef] [PubMed] 81. Lue, H.; Dewor, M.; Leng, L.; Bucala, R.; Bernhagen, J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cell Signal. 2011 ,23, 135–144. [CrossRef] [PubMed] 82. Shi, X.; Leng, L.; Wang, T.; Wang, W.; Du, X.; Li, J.; McDonald, C.; Chen, Z.; Murphy, J.W.; Lolis, E.; et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006,25, 595–606. [CrossRef] [PubMed] 83. Krockenberger, M.; Dombrowski, Y.; Weidler, C.; Ossadnik, M.; Honig, A.; Hausler, S.; Voigt, H.; Becker, J.C.; Leng, L.; Steinle, A.; et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 2008,180, 7338–7348. [CrossRef] [PubMed] 84. Ali, S.A.; Shi, V.; Maric, I.; Wang, M.; Stroncek, D.F.; Rose, J.J.; Brudno, J.N.; Stetler-Stevenson, M.; Feldman, S.A.; Hansen, B.G.; et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016,128, 1688–1700. [CrossRef] [PubMed] 85. Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.; et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013,368, 1509–1518. [CrossRef] [PubMed] 86. Ruella, M.; Barrett, D.M.; Kenderian, S.S.; Shestova, O.; Hofmann, T.J.; Perazzelli, J.; Klichinsky, M.; Aikawa, V.; Nazimuddin, F.; Kozlowski, M.; et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Investig. 2016 ,126, 3814–3826. [CrossRef] [PubMed] 87. Kailayangiri, S.; Altvater, B.; Spurny, C.; Jamitzky, S.; Schelhaas, S.; Jacobs, A.H.; Wiek, C.; Roellecke, K.; Hanenberg, H.; Hartmann, W.; et al. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology 2017,6, e1250050. [CrossRef] [PubMed] 88. Martín-Antonio, B.; Suñe, G.; Najjar, A.; Perez-Amill, L.; Velasco-de Andrés, M.; Lozano, F.; Lozano, E.; Bueno, C.; Estanyol, J.-M.; Muñoz-Pinedo, C.; et al. Natural killer cells transfer antimicrobial and antitumoral Histone H2AZ to kill multiple myeloma cells contributing to transmissible cytotoxicity. Blood 2016 ,128, 2115. Int. J. Mol. Sci. 2017,18, 1868 19 of 20 89. Benson, D.M., Jr.; Bakan, C.E.; Mishra, A.; Hofmeister, C.C.; Efebera, Y.; Becknell, B.; Baiocchi, R.A.; Zhang, J.; Yu, J.; Smith, M.K.; et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010 ,116, 2286–2294. [CrossRef] [PubMed] 90. Ray, A.; Das, D.S.; Song, Y.; Richardson, P.; Munshi, N.C.; Chauhan, D.; Anderson, K.C. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 2015, 10. [CrossRef] [PubMed] 91. Lee, Y.H.; Martin-Orozco, N.; Zheng, P.; Li, J.; Zhang, P.; Tan, H.; Park, H.J.; Jeong, M.; Chang, S.H.; Kim, B.S.; et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017,27, 1034–1045. [CrossRef] [PubMed] 92. Liu, Y.; Cheng, Y.; Xu, Y.; Wang, Z.; Du, X.; Li, C.; Peng, J.; Gao, L.; Liang, X.; Ma, C. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene 2017. [CrossRef] [PubMed] 93. Tallerico, R.; Cristiani, C.M.; Staaf, E.; Garofalo, C.; Sottile, R.; Capone, M.; Pico de Coana, Y.; Madonna, G.; Palella, E.; Wolodarski, M.; et al. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology 2017,6, e1261242. [CrossRef] [PubMed] 94. Schmidt, S.; Tramsen, L.; Hanisch, M.; Latge, J.P.; Huenecke, S.; Koehl, U.; Lehrnbecher, T. Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia. J. Infect. Dis. 2011,203, 430–435. [CrossRef] [PubMed] 95. Sporri, R.; Joller, N.; Albers, U.; Hilbi, H.; Oxenius, A. MyD88-dependent IFNγ production by NK cells is key for control of Legionella pneumophila infection. J. Immunol. 2006,176, 6162–6171. [CrossRef] [PubMed] 96. Garcia-Laorden, M.I.; Stroo, I.; Terpstra, S.; Florquin, S.; Medema, J.P.; de Vos, A.F.; van der Poll, T. Expression and Function of Granzymes A and B in Escherichia coli Peritonitis and Sepsis. Mediat. Inflamm. 2017 ,2017, 4137563. [CrossRef] [PubMed] 97. Garcia-Laorden, M.I.; Stroo, I.; Blok, D.C.; Florquin, S.; Medema, J.P.; de Vos, A.F.; van der Poll, T. Granzymes A and B Regulate the Local Inflammatory Response during Klebsiella pneumoniae Pneumonia. J. Innate Immun. 2016,8, 258–268. [CrossRef] [PubMed] 98. Baschuk, N.; Wang, N.; Watt, S.V.; Halse, H.; House, C.; Bird, P.I.; Strugnell, R.; Trapani, J.A.; Smyth, M.J.; Andrews, D.M. NK cell intrinsic regulation of MIP-1 α by granzyme M. Cell Death Dis. 2014 ,5, e1115. [CrossRef] [PubMed] 99. Wei, H.M.; Lin, L.C.; Wang, C.F.; Lee, Y.J.; Chen, Y.T.; Liao, Y.D. Antimicrobial Properties of an Immunomodulator—15 kDa Human Granulysin. PLoS ONE 2016,11, e0156321. [CrossRef] [PubMed] 100. Stenger, S.; Hanson, D.A.; Teitelbaum, R.; Dewan, P.; Niazi, K.R.; Froelich, C.J.; Ganz, T.; Thoma-Uszynski, S.; Melian, A.; Bogdan, C.; et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998,282, 121–125. [CrossRef] [PubMed] 101. Lu, C.C.; Wu, T.S.; Hsu, Y.J.; Chang, C.J.; Lin, C.S.; Chia, J.H.; Wu, T.L.; Huang, T.T.; Martel, J.; Ojcius, D.M.; et al. NK cells kill mycobacteria directly by releasing perforin and granulysin. J. Leukoc. Biol. 2014,96, 1119–1129. [CrossRef] [PubMed] 102. Dalbeth, N.; Callan, M.F. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheumatol. 2002,46, 1763–1772. [CrossRef] [PubMed] 103. Anthony, D.A.; Andrews, D.M.; Chow, M.; Watt, S.V.; House, C.; Akira, S.; Bird, P.I.; Trapani, J.A.; Smyth, M.J. A role for granzyme M in TLR4-driven inflammation and endotoxicosis. J. Immunol. 2010 ,185, 1794–1803. [CrossRef] [PubMed] 104. Sharma, M.; Merkulova, Y.; Raithatha, S.; Parkinson, L.G.; Shen, Y.; Cooper, D.; Granville, D.J. Extracellular granzyme K mediates endothelial activation through the cleavage of protease-activated receptor-1. FEBS J. 2016,283, 1734–1747. [CrossRef] [PubMed] 105. Wensink, A.C.; Kemp, V.; Fermie, J.; Garcia Laorden, M.I.; van der Poll, T.; Hack, C.E.; Bovenschen, N. Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes. Proc. Natl. Acad. Sci. USA 2014,111, 5974–5979. [CrossRef] [PubMed] Int. J. Mol. Sci. 2017,18, 1868 20 of 20 106. Jiang, W.; Chai, N.R.; Maric, D.; Bielekova, B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J. Immunol. 2011 ,187, 781–790. [CrossRef] [PubMed] 107. Santiago, L.; Menaa, C.; Arias, M.; Martin, P.; Jaime-Sanchez, P.; Metkar, S.; Comas, L.; Erill, N.; Gonzalez-Rumayor, V.; Esser, E.; et al. Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis. Arthritis Rheumatol. 2017,69, 320–334. [CrossRef] [PubMed] 108. Deng, A.; Chen, S.; Li, Q.; Lyu, S.C.; Clayberger, C.; Krensky, A.M. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J. Immunol. 2005,174, 5243–5248. [CrossRef] [PubMed] 109. Falschlehner, C.; Emmerich, C.H.; Gerlach, B.; Walczak, H. TRAIL signalling: Decisions between life and death. Int. J. Biochem. Cell Biol. 2007,39, 1462–1475. [CrossRef] [PubMed] 110. Barnhart, B.C.; Legembre, P.; Pietras, E.; Bubici, C.; Franzoso, G.; Peter, M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004,23, 3175–3185. [CrossRef] [PubMed] 111. Qadir, A.S.; Ceppi, P.; Brockway, S.; Law, C.; Mu, L.; Khodarev, N.N.; Kim, J.; Zhao, J.C.; Putzbach, W.; Murmann, A.E.; et al. CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. Cell Rep. 2017,18, 2373–2386. [CrossRef] [PubMed] 112. Hartwig, T.; Montinaro, A.; von Karstedt, S.; Sevko, A.; Surinova, S.; Chakravarthy, A.; Taraborrelli, L.; Draber, P.; Lafont, E.; Arce Vargas, F.; et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol. Cell. 2017 ,65, 730–742. [CrossRef] [PubMed] 113. Su, Z.; Yang, Z.; Xie, L.; DeWitt, J.P.; Chen, Y. Cancer therapy in the necroptosis era. Cell Death Differ. 2016 , 23, 748–756. [CrossRef] [PubMed] 114. Del Fabbro, E.; Skoro, N.; Brian, C. The prevalence of cachexia among patients with solid and hematologic malignancies at a National Cancer Institute (NCI)-designated cancer center in the 12 months prior to death. J. Clin. Oncol. 2014,32. [CrossRef] © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).